dWe sequenced a novel conjugative multidrug resistance IncF plasmid, p42-2, isolated from Escherichia coli strain 42-2, previously identified in China. p42-2 is 106,886 bp long, composed of a typical IncFII-type backbone (ϳ54 kb) and one distinct acquired DNA region spanning ϳ53 kb, harboring 12 antibiotic resistance genes [bla CTX-M-55 , oqxA, oqxB, fosA3, floR, tetA(A), tetA(R), strA, strB, sul2, aph(3=)-II, and ⌬bla TEM-1 ]. The spread of these multidrug resistance determinants on the same plasmid is of great concern and, because of coresistance to antibiotics from different classes, is therapeutically challenging.
Widespread antibiotic resistance poses an enormous threat for human and animal health worldwide (1). This problem has been exacerbated in recent years with the emergence of multidrug resistance (MDR) plasmids conferring resistance to most classes of antimicrobials (2). Plasmids of the incompatibility F (IncF) group, representing one of the most frequently encountered plasmid types (3), have frequently been associated with MDR phenotypes, including extended-spectrum -lactamases (ESBLs) and plasmid-mediated quinolone resistance (PMQR) genes (4, 5). In a previous study of ours, IncF plasmids recovered from Escherichia coli strains of food-producing and companion animals were investigated, and most of them carried numerous resistance determinants, such as bla CTX-M , rmtB, oqxAB, and floR (4, 6). The spread of these multiresistance plasmids has prompted worldwide concern because of coresistance to multiple antimicrobial agents that facilitates the survival of bacteria under the selective pressure of antibiotics. Herein, we analyzed a common subtype IncF plasmid, F33:AϪ:BϪ (FII, FIA, FIB [FAB] formula); this plasmid, designated p42-2, contains 12 different resistance genes and was fully sequenced, and the data were compared with those of other IncF plasmids.E. coli 42-2 was recovered from the feces of a healthy duck in Guangzhou, China. Conjugation was performed by mixing E. coli 42-2 and E. coli C600 in a liquid medium and isolating for E. coli C600 (p42-2) by selection on MacConkey agar containing streptomycin (1,000 mg/liter) and cefotaxime (2 mg/liter) as previously described (4, 6). p42-2 was extracted from the E. coli C600 transconjugant using a commercial kit (Qiagen midikit; Qiagen, Germany). Sequencing of p42-2 was performed on an Illumina IIx genome analyzer with a 500-bp paired-end library (approximately 100 million available reads, 935-fold genome coverage) and a 2,000-bp paired-end library (ϳ337 million available reads, 3,150-fold genome coverage). These raw data were assembled by SOAPdenovo (7). Gene prediction and annotation were performed using RAST tools (8). The sequence comparison and map generation were performed using BLAST (http://blast.ncbi.nlm.nih.gov) and Easyfig version 2.1 (9).Plasmid p42-2 confers resistance to ampicillin, chloramphenicol, kanamycin, streptomycin, sulfonamides/trimethoprim, tetracycline, olaquindox, fosfomycin, cephalosporin, and florfenicol. Because of its ...